CVS agrees to pay $315 million to settle federal opioid dispensing case

By ··2 min read·3 sources

The Justice Department announced that CVS Pharmacy will pay $315 million to resolve Controlled Substances Act and False Claims Act allegations that it filled unlawful opioid prescriptions and billed federal programs for them. CVS admitted no liability and signed a compliance agreement with the DEA.

The U.S. Department of Justice announced on October 13, 2026, that CVS Pharmacy Inc. and related corporate entities agreed to pay $315 million to resolve allegations that they unlawfully dispensed opioids and other controlled substances and sought payment from federal healthcare programs for many of those prescriptions. The covered conduct runs from October 17, 2013, through December 2, 2025.

The government alleged that CVS pharmacies dispensed excessive quantities of opioids, filled prescriptions too early, filled so-called trinity combinations of an opioid, a benzodiazepine and a muscle relaxant, and filled prescriptions from prescribers operating as pill mills, despite clear red flags. It alleged that corporate performance metrics, incentive pay and staffing policies put profit ahead of patient safety and discouraged pharmacists from warning one another about problem prescribers. The United States filed its complaint on December 13, 2024, in the U.S. District Court for the District of Rhode Island, intervening in a whistleblower case brought by former CVS employee Hillary Estright, United States ex rel. Estright v. CVS Health Corporation, et al., No. 22-cv-00222.

The department said the claims resolved are allegations only and that there has been no determination of liability. CVS said it strongly disagreed with the claims and that the settlement admits no wrongdoing. The relator's share had not been determined at announcement.

Alongside the payment, CVS entered a memorandum of agreement with the DEA. It must set up a hotline for employees and the public to report suspected illegal dispensing, proactively monitor dispensing patterns across its pharmacies and create a process for evaluating prescribers suspected of illegal prescribing. The DEA's Office of Diversion Control led the case, with U.S. Attorney's Offices in Rhode Island, the Eastern District of Virginia, the Eastern District of Texas and Hawaii.

The settlement follows Walgreens' 2025 resolution of a similar Justice Department dispensing case. CVS separately remains party to the roughly $5 billion national opioid settlement with state and local governments agreed in 2022.

Sources

  1. justice.gov · justice.gov/opa/pr/cvs-agrees-pay-315m-illegally-filling-unlawful-opioid-prescriptions-and…
  2. courthousenews.com · courthousenews.com/cvs-to-pay-315-million-settlement-over-opioid-prescriptions/
  3. kttc.com · kttc.com/2026/10/13/cvs-pay-315m-over-opioid-prescriptions-major-doj-settlement/

Cite this report

The Precedent. "CVS agrees to pay $315 million to settle federal opioid dispensing case." October 14, 2026. https://theprecedent.org/article/cvs-agrees-to-pay-315-million-to-settle-federal-opioid-dispensing-case

Companies in this report